BIIB Stock Cash Flow Statements

Biogen Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Biogen Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2010-12-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31

cash flow from operating activities:
net income	634,800,000	240,500,000	266,700,000	388,500,000	583,600,000	393,400,000	248,900,000	-68,300,000	593,300,000	387,600,000	549,500,000	1,134,900,000	1,058,700,000	218,500,000	-20,500,000	318,000,000	1,025,500,000	404,600,000	357,600,000	703,900,000	1,606,400,000	1,392,600,000	1,439,700,000	1,545,900,000	1,494,100,000	1,408,800,000	944,900,000	1,442,900,000	915,000,000	1,171,200,000	-166,300,000	1,226,100,000	862,800,000	747,500,000	647,900,000	1,030,200,000	1,048,400,000	969,200,000	828,708,000	1,019,493,000	924,825,000	820,174,000	723,132,000	479,728,000	487,616,000	490,670,000	426,749,000	398,399,000	387,141,000	302,366,000	897,946,179	206,654,000	206,788,000	206,628,000	163,097,000	201,150,000	119,381,000	186,140,000	131,501,000	108,556,000	156,599,000	-170,613,000	122,969,000	55,562,000	27,185,000	34,506,000	43,458,000
adjustments to reconcile net income to net cash flow from operating activities:
depreciation and amortization	194,300,000	183,200,000	184,000,000	182,800,000	158,900,000	147,500,000	140,100,000	125,000,000	117,400,000	112,300,000	119,800,000	120,700,000	134,800,000	143,100,000	134,700,000	133,200,000												346,500,000	171,500,000	168,900,000				512,000,000	177,400,000	180,200,000	175,400,000	149,700,000	156,300,000	151,577,000	144,586,000	147,937,000	164,139,000	190,963,000	147,477,000	128,427,000	97,453,000	94,203,000	90,624,000	83,945,000													123,230,000	97,524,000	109,751,000	98,822,000	96,111,000
impairment of intangible assets			40,000,000												0	43,400,000
excess and obsolescence charges related to inventory	7,000,000	7,300,000	33,200,000	24,300,000	16,900,000	27,500,000	62,300,000	25,300,000	19,400,000	17,400,000	14,600,000	16,000,000	24,100,000	281,500,000
amortization of acquired inventory step-up	52,500,000	51,400,000	44,900,000	50,900,000
share-based compensation	74,900,000	81,000,000	75,100,000	72,700,000	70,600,000	72,800,000	54,900,000	62,200,000	71,500,000	75,600,000	67,200,000	63,600,000	55,700,000	67,600,000	58,800,000	55,700,000	54,100,000	70,000,000	49,000,000	33,500,000	48,100,000	67,700,000	38,400,000	45,900,000	52,300,000	45,700,000	38,500,000	37,300,000	38,300,000	43,400,000	30,600,000	30,100,000	30,300,000	37,000,000	37,000,000	33,700,000	38,800,000	45,300,000	29,863,000	37,860,000	41,614,000	52,063,000	37,516,000	46,340,000	37,464,000	30,630,000	36,757,000	27,911,000	28,071,000	32,396,000	167,691,406		36,692,000	33,118,000	34,529,000
contingent consideration	13,200,000	9,600,000	3,900,000								-195,400,000	-2,100,000	-4,500,000	-7,100,000	-1,600,000	-15,600,000	300,000	-33,800,000	-62,800,000	-29,000,000	10,100,000	-4,600,000	2,600,000	-57,800,000	-20,000,000	11,500,000	79,300,000
deferred income taxes	-31,300,000	-27,800,000	-58,400,000	-52,600,000	-87,000,000	39,900,000	71,900,000	-206,800,000	-106,400,000	-64,500,000	-28,800,000	-92,300,000	-48,500,000	1,000,000	323,300,000	-127,300,000	-607,800,000	-15,000,000	-62,900,000	31,700,000	143,300,000	36,900,000	38,700,000	-43,200,000	-156,400,000	228,000,000	153,100,000	12,600,000	-110,500,000	53,100,000	131,400,000	-19,200,000	-96,600,000	76,100,000	-118,200,000	-26,600,000	-39,100,000	8,900,000	40,202,000	-95,155,000	-107,386,000	16,739,000	-66,948,000	-79,558,000	-48,140,000	-51,522,000	-66,525,000	-43,027,000	-39,955,000	-3,876,000	-81,348,756	-81,958,000	-42,834,000	-21,940,000	7,183,000	-41,189,000	-22,194,000	-23,187,000	5,015,000	-26,560,000	-33,679,000	-19,566,000	-26,532,000	16,672,000	-32,651,000	-73,731,000	-25,829,000
(gain) loss on strategic investments	-7,700,000	40,900,000	78,700,000	-38,900,000	30,300,000	31,300,000	1,400,000	302,500,000	-106,400,000	79,600,000	105,600,000	-109,000,000	78,200,000	191,100,000	116,300,000	426,900,000	-154,000,000	437,600,000
gain on sale of priority review voucher			0	0
other	9,300,000	6,700,000	64,500,000	30,100,000	39,600,000	25,400,000	49,600,000	38,100,000	29,100,000	31,400,000	60,400,000	35,600,000	68,900,000	43,300,000	1,200,000	88,600,000	40,700,000	71,700,000	21,100,000	24,800,000	39,600,000	45,700,000	-18,200,000	-3,700,000	40,400,000	50,700,000	-900,000	-110,600,000	16,300,000	26,100,000	35,200,000	53,400,000	55,400,000	18,100,000	57,800,000	13,600,000	40,000,000	-20,200,000	50,636,000	37,372,000	27,113,000	-32,921,000	7,263,000	-71,476,000	5,918,000	-9,053,000	-33,442,000	27,113,000	8,003,000	-29,073,000													1,193,000			-536,000	-1,369,000
changes in operating assets and liabilities, net of effects of business acquired:
accounts receivable	10,500,000	-181,000,000	94,700,000	115,300,000	-31,400,000	43,700,000	137,800,000	-98,300,000	-55,400,000	77,200,000	-93,900,000	-42,200,000	20,200,000	-87,500,000	167,000,000	-53,700,000	174,300,000	37,200,000	138,500,000	133,100,000	-30,400,000	-238,400,000	71,200,000	500,000	133,700,000	-136,600,000	48,800,000	-66,800,000	-53,200,000	-134,000,000	-209,800,000	75,400,000	-105,500,000	-195,700,000	-3,300,000	-173,100,000	95,000,000	-160,000,000	92,608,000	-24,701,000	89,380,000	-128,287,000	8,724,000	-197,685,000	-34,172,000	-110,142,000	-75,546,000	29,244,000	78,308,000	-89,066,000	-99,154,281	37,772,000	-9,035,000	-31,599,000	-54,703,000	-12,978,000	-16,724,000	-34,357,000	-6,642,000	-18,164,000	2,036,000	-11,396,000	-9,485,000	-5,245,000	-7,635,000	17,797,000	1,335,000
due from anti-cd20 therapeutic programs	-66,200,000	70,400,000	-12,200,000	-800,000	-55,800,000	40,700,000	-7,700,000	9,800,000	-44,300,000	37,600,000	-16,000,000	20,600,000	-46,500,000	22,900,000	-12,300,000	22,200,000	-52,500,000	43,800,000	113,700,000	-86,100,000	70,500,000	78,600,000
inventory	-89,900,000	62,000,000	-66,400,000	-19,200,000	-110,500,000	-77,700,000	-96,000,000	30,200,000	-93,000,000	27,900,000	18,100,000	-95,000,000	-100,700,000	-142,600,000	-139,800,000	-128,800,000	-81,300,000	-112,500,000	-45,700,000	-82,400,000	-126,000,000	-62,200,000	-66,500,000	-61,400,000	-20,300,000	129,000,000	-20,200,000	8,200,000	-42,700,000	2,600,000	75,800,000	-85,000,000	-39,100,000	-46,200,000	-10,500,000	-26,800,000	-39,700,000	-88,600,000	-24,013,000	-69,093,000	-59,787,000	-21,507,000	-55,709,000	-16,980,000	-53,643,000	-68,362,000	-60,809,000				-4,543,311	-19,828,000	-6,189,000	-21,843,000	-6,344,000	-12,326,000	-18,785,000	-28,890,000	-23,191,000	-13,664,000	605,000	-8,071,000	-15,507,000	21,748,000	-4,268,000	-19,763,000	-30,449,000
accrued expense and other current liabilities	-18,200,000	-300,500,000	108,800,000	31,400,000	61,500,000	-177,100,000	-495,500,000	421,000,000	167,900,000	-295,000,000	-745,700,000	-1,700,000	1,095,600,000	-461,600,000	147,900,000	-54,900,000	95,200,000	-283,600,000
income tax assets and liabilities	-603,800,000	69,100,000	16,400,000	69,800,000	-5,500,000	-2,200,000	-184,200,000	-32,400,000	-147,400,000	65,000,000	-42,100,000	-34,300,000	-167,800,000	101,900,000	-29,700,000	89,000,000	106,700,000	64,800,000	-82,800,000	-489,300,000	281,600,000	223,000,000	-48,500,000	-242,300,000	136,600,000	170,300,000	6,100,000	132,200,000	-74,200,000	257,600,000	1,133,400,000	285,200,000	80,400,000	-195,100,000
other changes in operating assets and liabilities	-22,000,000	-53,500,000	-113,000,000	37,300,000	-46,900,000	-56,100,000	-2,500,000	-15,900,000	41,300,000	-96,800,000	-107,900,000	149,900,000	79,600,000	-213,600,000	-56,900,000	9,700,000	-16,400,000	-80,900,000	-40,100,000	-106,900,000	-8,600,000	18,500,000		19,300,000	90,800,000	-171,100,000		-89,700,000	28,700,000	-20,000,000		-62,900,000	-153,000,000	-34,300,000		12,000,000	35,300,000	14,800,000		-55,285,000	3,337,000	-69,711,000	31,407,000	-75,338,000	129,402,000	33,654,000	35,212,000	38,262,000	-50,615,000	-20,036,000
net cash flow provided by operating activities	160,900,000	259,300,000	760,900,000	935,600,000	625,800,000	553,200,000	12,500,000	592,400,000	487,000,000	455,300,000	-175,000,000	661,000,000	736,500,000	161,800,000	838,300,000	805,300,000	1,227,300,000	769,000,000
cash flow from investing activities:
purchases of property, plant and equipment	-26,600,000	-37,100,000	-39,300,000	-35,000,000	-33,500,000	-45,900,000	-65,200,000	-74,200,000	-71,000,000	-66,600,000	-86,400,000	-59,100,000	-36,900,000	-57,900,000	-51,600,000	-42,000,000	-71,900,000	-92,600,000	-86,000,000	-84,100,000	-105,000,000	-149,700,000	-110,400,000	-90,100,000	-186,900,000	-127,100,000	-225,900,000	-163,200,000	-186,800,000	-194,700,000	-230,600,000	-229,100,000	-197,700,000	-210,000,000	-182,100,000	-170,300,000	-136,800,000	-126,900,000	-186,115,000	-229,197,000	-129,858,000	-97,830,000	-64,002,000	-54,306,000	-80,188,000	-54,151,000	-33,289,000	-58,064,000	-72,896,000	-54,551,000	-172,930,780	-53,993,000	-64,868,000	-71,062,000	-86,031,000	-108,356,000	-58,502,000	-79,846,000	-37,402,000
proceeds from sale of equity interest in samsung bioepis			0	0			0	0			0
proceeds from sale of priority review voucher			0	-14,400,000
acquisitions of intangible assets	0	-10,000,000	-27,000,000	-95,000,000	-9,100,000	-75,000,000	0	-13,400,000	-16,000,000	-5,000,000	-1,000,000	0			-16,900,000				-15,000,000	0	0	-37,000,000					0	0			-65,000,000	-50,100,000	-5,100,000	-855,200,000	-1,200,000
proceeds from sales of strategic investments			48,000,000	39,200,000	1,900,000	55,600,000	13,400,000	3,000,000	69,400,000	33,800,000					2,300,000	0	0	91,200,000	74,400,000	0	0	500,000	3,300,000	166,300,000
net cash flow provided by investing activities	-57,000,000	-47,300,000	-18,600,000	-1,181,100,000	466,500,000	-66,000,000	-652,300,000	-1,742,200,000	-753,500,000	-953,000,000	-141,100,000	1,672,200,000	693,500,000	-648,000,000				-64,700,000
cash flow from financing activities:
payments related to issuance of stock for share-based compensation arrangements	6,100,000	-24,300,000	3,500,000	6,000,000	6,100,000	-46,900,000	3,700,000	6,600,000	5,500,000	-60,100,000	3,900,000	5,700,000	9,300,000	-20,800,000	7,600,000	5,900,000	12,900,000	-27,100,000	7,200,000	7,400,000	10,400,000	-29,600,000		6,700,000	8,600,000	-32,200,000	4,600,000	7,600,000	6,900,000	-21,200,000	5,400,000	7,100,000	7,700,000	-25,500,000
proceeds from borrowings							0												100,000	0																			-436,000																	617,000
repayments of borrowings																																																				0	0	-12,474,000	-1,500,000,000	0
net cash flow provided by financing activities	-11,700,000	-23,000,000	7,900,000	-6,600,000	-245,200,000	-439,600,000	-646,100,000	848,600,000	-9,800,000	-43,400,000	-7,400,000	-1,251,900,000	-471,500,000	-16,500,000																																							134,828,000	-250,129,000	-787,532,000			64,412,000	24,401,000
net increase in cash and cash equivalents	92,200,000	189,000,000	750,200,000	-252,100,000	847,100,000	47,600,000	-1,285,900,000	-301,200,000	-276,300,000	-541,100,000	-323,500,000	1,081,300,000	958,500,000	-502,700,000	735,400,000	-174,800,000	510,100,000	-80,700,000	-934,600,000	-184,200,000	-197,600,000	-335,100,000	552,200,000	640,000,000	-522,500,000	1,019,000,000	-1,166,900,000	1,141,900,000	-2,840,700,000	2,535,100,000	40,700,000	362,000,000			273,700,000	722,200,000	246,300,000	-192,400,000	-2,765,537,000	2,813,095,000	-209,680,000	311,022,000	38,106,000	225,494,000	29,008,000	-271,792,000	96,456,000			-221,021,000	185,032,281	-390,304,000	547,551,000	-224,330,000	29,030,000			830,524,000	119,348,000	246,695,000	70,061,000	-191,368,000	-32,303,000	271,676,000	-341,908,000	361,957,000	66,996,000
effect of exchange rate changes on cash and cash equivalents	68,300,000	34,300,000	-74,400,000	42,400,000	-12,600,000	-23,100,000	47,900,000	-28,700,000	-4,100,000	20,000,000	67,200,000	-52,300,000	-61,200,000	-9,400,000	-15,800,000	-25,400,000	14,400,000	-33,000,000	41,000,000	24,100,000	-8,800,000	12,700,000	17,600,000	-19,500,000	2,700,000	-400,000	4,800,000	-5,400,000	-17,100,000	-900,000	-15,000,000	16,600,000	29,900,000	7,900,000	-32,000,000	600,000	-15,000,000	15,100,000	-15,442,000	-6,170,000	13,707,000	-37,895,000	-3,510,000	545,000	6,296,000	997,000	-3,875,000	3,768,000	-6,353,000	4,618,000	-7,368,149	1,988,000	-3,343,000	2,324,000	-193,000	-542,000	-348,000	117,000	215,000	88,000
cash and cash equivalents, beginning of the period	0	2,375,000,000		0	0	1,049,900,000		0	0	3,419,300,000		0	0	2,261,400,000		0	0	1,331,200,000		0	0	2,913,700,000		0	0	1,224,600,000		0	0	1,573,800,000		0	0	2,326,500,000		0	0	1,308,000,000		0	0	1,204,924,000	0	602,562,000	0	0	570,721,000	0	0	514,542,000			0	0	659,662,000		0	0	661,377,000		0	0	568,168,000		0	0	209,447,000
cash and cash equivalents, end of the period	160,500,000	2,598,300,000		-209,700,000	834,500,000	1,074,400,000		-329,900,000	-280,400,000	2,898,200,000		1,029,000,000	897,300,000	1,749,300,000		-200,200,000	524,500,000	1,217,500,000		-160,100,000	-206,400,000	2,591,300,000		620,500,000	-519,800,000	2,243,200,000		1,136,500,000	-2,857,800,000	4,108,000,000		378,600,000	245,500,000	924,000,000		722,800,000	231,300,000	1,130,700,000		2,806,925,000	-195,973,000	1,478,051,000	34,596,000	828,601,000	35,304,000	-270,795,000	663,302,000	-5,088,000	158,672,000	298,139,000			544,208,000	-222,006,000	688,499,000		-1,174,255,000	830,641,000	780,940,000		69,490,000	-190,761,000	535,865,000		-341,908,000	361,957,000	276,443,000
repayment of borrowings				0																0								0
(gain) loss on equity method investment															-17,700,000
gain on sale of equity interest in samsung bioepis											0	0
gain on sale of building											0
proceeds from sales and maturities of marketable securities							0	5,698,600,000	1,275,500,000	406,700,000	566,300,000	1,643,200,000	917,900,000	543,600,000	1,377,300,000	575,400,000	633,500,000	819,200,000	2,058,700,000	1,360,800,000	1,490,600,000	2,389,300,000	2,139,400,000	611,800,000	1,766,600,000	1,489,200,000	1,179,000,000	1,192,000,000	2,733,800,000	4,068,900,000	1,093,300,000	888,100,000	1,700,200,000	1,884,300,000	2,193,100,000	2,362,200,000	1,642,500,000	1,181,100,000	699,626,000	2,387,857,000	601,954,000	373,563,000	560,013,000	757,512,000	620,511,000	75,201,000	4,329,506,000	489,450,000	599,497,000	824,434,000	2,666,203,637				917,972,000			1,606,127,000	803,675,000	319,042,000	445,040,000
purchases of marketable securities							0	-1,020,400,000	-2,799,100,000	-1,321,200,000	-642,600,000	-494,300,000	-1,178,100,000	-1,133,500,000	-1,436,100,000	-745,700,000	-713,600,000	-913,300,000	-1,748,600,000	-895,200,000	-2,069,200,000	-1,684,700,000	-1,200,500,000	-1,977,000,000	-1,250,100,000	-825,000,000	-1,601,000,000	-1,319,500,000	-2,855,100,000	-1,919,200,000	-1,261,300,000	-1,557,900,000	-1,279,300,000	-1,256,700,000	-2,281,500,000	-1,798,400,000	-1,918,900,000	-1,914,400,000	-1,994,758,000	-2,825,096,000	-1,722,088,000	-322,958,000	-1,121,395,000	-666,211,000	-855,635,000	-457,294,000	-1,160,680,000	-938,409,000	-576,842,000	-677,092,000	-1,987,022,231	-1,362,768,000	-740,897,000	-628,500,000	-431,659,000	-743,726,000	-333,147,000	-989,821,000	-878,550,000	-352,644,000	-268,241,000
acquisition of reata, net of cash acquired							-590,500,000
acquisition of hi-bio, net of cash acquired			0
proceeds from sale of building											0
purchase of treasury stock																																							-2,001,810,000	-2,955,997,000					-359,285,000	0	-41,023,000	-53,220,000	-446,780,000	-463,171,000		-179,171,000	0							0	-319,902,000				0	-154,115,000	-168,475,000
repayments of borrowings and premiums paid
net (distribution) contribution to noncontrolling interest							8,100,000	2,500,000	1,500,000	200,000	200,000	100,000	11,900,000	200,000
cash and cash equivalents, beginning of the year
cash and cash equivalents, end of the year
amortization of inventory step-up						44,100,000
repayment of borrowings and premiums paid						-400,000,000
acquired in-process research and development															0	0			0	0	0	75,000,000					0	27,500,000	75,000,000	10,000,000	240,000,000	0																											18,405,000
proceeds from divestiture of hillerød, denmark manufacturing operations															0	0	0	28,100,000					0
(gain) loss on equity method investments												0	-5,900,000	3,300,000
purchases of treasury stock												-250,000,000				-750,000,000	-450,000,000	-600,000,000		-1,250,000,000	-2,808,900,000	-2,220,200,000	-2,093,100,000	-717,900,000	-2,401,500,000	-655,800,000	-1,352,600,000	0	-2,750,000,000	-250,000,000	0	0	-781,800,000	-583,600,000
changes in operating assets and liabilities, net:
(gain)/loss on divestiture of hillerød, denmark manufacturing operations
purchase of sangamo therapeutics, inc. stock																			0	0
purchase of denali therapeutics inc. stock																			0
purchase of sage therapeutics, inc. stock
repayments of borrowings and premiums paid on debt exchange
proceeds from sale of equity in samsung bioepis
proceeds from the sales of strategic investments
repayment of borrowings and premiums paid on debt exchange																0	-700,000	-169,300,000
contingent consideration paid related to fumapharm ag acquisition																								0	0	-300,000,000		-300,000,000	-300,000,000	-600,000,000
acquisition of nightstar therapeutics plc, net of cash acquired																							0	0
net cash flow used in financing activities															9,800,000	-746,500,000	-564,500,000	-785,000,000
net cash flow used in investing activities																-233,600,000
cash proceeds from settlement of swap
net distribution to noncontrolling interest																0								0			500,000	2,000,000
gain on interest rate swap
loss on equity method investment																	-34,300,000	18,200,000	-18,000,000
depreciation, amortization and impairments																		146,900,000		134,000,000	112,900,000	119,900,000	113,000,000	329,500,000	117,000,000	121,100,000
cash flows from operating activities:
adjustments to reconcile net income to net cash flows from operating activities:
(gain)/loss on divestiture of hillerod, denmark manufactuing operations
unrealized (gain) loss on strategic investments																			-723,600,000	81,500,000	-101,700,000	62,000,000		9,400,000	175,800,000	-375,000,000
accrued expenses and other current liabilities																			-218,700,000	814,300,000	-94,000,000	-347,400,000	349,300,000	107,000,000	-77,700,000	-138,400,000	364,800,000	87,400,000	135,100,000	-121,800,000	277,100,000	-52,200,000	231,900,000	-684,200,000	793,300,000	-60,900,000	18,500,000	-180,800,000	248,732,000	-4,603,000	35,538,000	-205,467,000	141,069,000	-171,368,000			-180,910,000	52,102,000	134,004,000	-82,031,000	130,857,623	-6,970,000			65,682,000	8,895,000	24,258,000	-14,187,000	13,494,000	78,683,000	17,716,000	-22,635,000	-59,952,000	241,000	17,669,000	77,371,000	-7,727,000
net cash flows from operating activities																			-367,100,000	1,181,100,000	1,948,500,000	1,467,300,000	1,960,200,000	1,694,900,000	1,964,000,000	1,459,500,000	1,895,400,000	1,735,900,000	1,099,300,000	1,457,100,000	1,518,300,000	1,628,300,000	1,169,200,000	235,200,000	1,576,600,000	986,600,000	995,800,000	963,400,000	1,040,395,000	895,448,000	1,047,220,000	733,037,000	990,593,000	104,626,000	671,922,000	625,212,000	178,939,000	541,784,000	635,581,000	194,625,000	1,623,479,383	409,292,000	512,193,000	276,022,000	366,985,000	345,862,000	210,426,000	202,018,000	262,329,000	241,805,000	259,838,000	183,372,000	156,253,000	274,740,000	173,095,000	228,782,000	212,886,000
cash flows from investing activities:
purchase of ionis pharmaceuticals, inc. stock																											0	800,000
proceeds from divesiture of hillerod, denmark manufacturing operations
investment in samsung bioepis
net cash flows from investing activities																			-166,400,000	-52,400,000	-832,700,000	442,900,000			-110,800,000	238,800,000			-1,148,500,000	1,346,600,000												-502,771,000		5,993,000			155,941,000			618,000			-99,470,000	-250,223,000	449,577,000	-616,635,000					121,491,000	-385,374,000	-272,212,000	-70,944,000	-534,294,000	1,027,693,000	-4,714,000
cash flows from financing activities:
net contribution (distribution) to noncontrolling interest
contingent consideration payments
net cash flows (used in) financing activities
loss on divestiture of hillerød, denmark manufacturing operations																							-40,200,000
net cash flows used in financing activities																				-1,312,900,000	-1,313,400,000	-2,245,300,000	-2,116,400,000	-689,000,000	-2,375,700,000	-679,300,000	-1,437,000,000	25,100,000	-2,791,500,000	-268,600,000		-19,500,000	-751,000,000	-901,400,000											-318,522,000	-170,763,000	-238,424,000	-28,250,000	-417,440,000	-416,264,000	-1,782,908,155
proceeds from settlement of net investment hedge
other liabilities																																																							9,957,000	13,652,000	26,437,000	-1,382,000	2,587,000
contingent consideration related to fumapharm ag acquisition																															-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	0	-250,000,000
net contribution (distribution) to noncontrolling interests
net cash contribution to bioverativ, inc.
net cash flows used in investing activities																											-1,625,300,000				-769,500,000	-1,246,800,000	-202,600,000	-744,200,000	-581,700,000	36,200,000	-736,100,000	-1,203,200,000	-1,807,529,000	-989,937,000					-324,392,000			-522,390,000											-167,382,000
loss on assets and liabilities held for sale																									-2,300,000	115,500,000
other assets																																																			-12,561,565	-21,187,000	32,325,000	-4,716,000	-2,711,000	71,495,000	-58,372,000	5,950,000	-18,835,000	-24,264,000	219,000
net cash contribution to bioverativ inc.																																0
acquisitions of businesses, net of cash acquired
net cash flows from financing activities																																			-721,200,000	-300,600,000	-13,400,000	47,400,000	-1,998,403,000	2,907,584,000	-3,537,000	80,756,000		114,875,000																			83,656,000	67,880,000	19,291,000	-894,518,000	-141,176,000
depreciation, amortization and acquired in-process research and development																																177,400,000
net cash contribution to bioverativ																																		-302,700,000
net decrease in cash and cash equivalents																																		-1,410,400,000														-8,856,000
proceeds from issuance of stock for share-based compensation arrangements																																			8,500,000	11,300,000	9,400,000	14,500,000	8,691,000	10,782,000	9,113,000	25,614,000	11,114,000	22,363,000	17,365,000	17,185,000	21,817,000	15,197,000	19,001,000	24,080,000	183,405,553
excess tax benefit from share-based compensation																																																			13,142,284
changes in other tax assets and liabilities
acquisitions of business, net of cash acquired																																								0	0	-198,798,000	0	-25,000,000				0
excess tax benefit from share-based awards																																				2,900,000
current taxes payable																																					-376,800,000	225,100,000			-52,000,000	154,017,000
excess tax benefit from stock options																																						8,300,000		1,088,000	3,261,000	66,429,000	4,484,000	79,456,000								-566,000	-8,976,000	-10,822,000	-7,626,000	-38,266,000	-21,560,000	-4,647,000	-5,193,000
other long-term liabilities and taxes payable
due from unconsolidated joint business																																																			-28,642,171	-10,383,000	-12,321,000	-24,661,000	7,126,000	-5,414,000	1,196,000	-10,714,000	16,954,000	-11,389,000	7,543,000	-23,887,000	84,000	484,000	-598,000	-2,997,000	-497,000
acquisition of tysabri rights																																													0
acquisitions of businesses
repayment of borrowings under senior notes																																													0	-2,340,000	-450,000,000
purchases of reverse repurchase agreements																																															-2,968,000,000
proceeds from borrowings under line of credit facility																																															200,000,000
acquisition of stromedix, inc., net of cash acquired																																																		-72,401,000
depreciation and amortization of property, plant and equipment, and intangible assets
fair value adjustment of contingent consideration
excess tax benefit from shared-based compensation
write-down of inventory to net realizable value																																																			11,798,082	7,378,000	12,634,000	5,452,000	4,386,000	2,020,000	4,745,000	8,117,000	6,717,000	381,000	559,000	8,751,000	3,298,000	18,333,000	16,102,000	8,308,000	41,304,000
impairment of marketable securities, investments and other assets																																																			20,826,681
non-cash interest income, foreign exchange remeasurement gain, net and other
realized (gain) loss on sale of marketable securities and strategic investments
other liabilities and taxes payable																																																			17,650,436	54,291,000
acquisitions																																																			-72,436,024
acquisition of a variable interest entity																																																			-84,867,048
proceeds from the sale of property, plant and equipment
purchases of intangible assets
purchases of other investments																																																			-4,486,501		-5,649,000	-2,390,000	-9,221,000		-3,704,000	-2,932,000	-12,886,000		-1,275,000	-2,211,000	-2,094,000
proceeds from the sale of strategic investments
collateral received under securities lending																																																				148,138,000	-31,173,000	-22,263,000	83,516,000
change in cash overdraft																																																			11,778,414
acquisition of noncontrolling interests
net distributions to noncontrolling interests
net proceeds from financing arrangement for the sale of the san diego facility
repayments on financing arrangement for the sale of the san diego facility
obligation under securities lending
depreciation and amortization of property, plant and equipment and intangible assets																																																			353,840,911
realized gain on sale of marketable securities and strategic investments																																																					9,702,000
(gain) loss on disposal of property, plant and equipment
acquisition of noncontrolling interest
proceeds from the issuance of stock for share-based compensation arrangements
net contributions (to) from noncontrolling interests
non-cash interest income and foreign exchange remeasurement gain																																																			5,806,876
net contributions from noncontrolling interests
acquired in process research and development
cash received upon termination of interest rate swap
(gain) loss on sale of property, plant and equipment
net cash flows from in investing activities
loss on disposal of property, plant and equipment
proceeds from the sale of a strategic equity investment
net distributions to noncontrolling interest
net contributions from noncontrolling interest
non-cash interest income and foreign exchange remeasurement
acquired in process research and development and license
gain on sale of property, plant and equipment
acquisitions, net of cash acquired																																																				0	0	0	-25,000,000	-3,500,000	-50,000,000
proceeds from sale of property, plant and equipment																																																								-143,000	16,742,000	0	70,000	38,274,000	85,000	2,006,000	33,851,000
repayments of long-term debt																																																								0
net capital contribution from noncontrolling interest
supplemental cash flow disclosures:
cash paid during the year for:
interest
income taxes
non-cash financing activity:
conversion of subordinated notes to common and treasury stock
collateral received under securities leading
net income attributable to biogen idec inc.
depreciation and amortization of fixed and intangible assets																																																												87,217,000
noncontrolling interest in subsidiaries
impairment of investments and other assets																																																				30,142,000	16,051,000	6,559,000	8,892,000	18,279,000	653,000	3,053,000	2,460,000		582,000				17,536,000	0	14,588,000
changes in assets and liabilities, net:
adjustments to reconcile net income to net cash flows from operating activities depreciation and amortization of fixed and intangible assets																																																											88,815,000
minority interest in subsidiaries																																																				1,773,000	1,013,000
gain on settlement of license agreements
share based compensation
non-cash interest income and foreign exchange translation gain
facility impairments and (gain) loss on disposition
proceeds from sale of product line
purchase of other investments
proceeds from issuance of stock for share based compensation arrangements																																																				11,454,000	77,500,000	61,221,000	28,311,000	241,744,000
issuance of notes to fumedica
adjustments to reconcile net income to net cash flows from operating activities depreciation and amortization of fixed & intangible assets																																																							106,932,000
in-process research & development																																																					0
non-cash interest expense																																																					-23,439,000	4,009,000	8,142,000
proceeds from sales and maturities of marketable debt securities																																																					743,116,000
proceeds from sale of property, plant, and equipment
change in cash overdrafts																																																					17,179,000	-12,517,000	13,390,000		-9,573,000	-645,000	3,000		-5,842,000	-12,967,000	7,664,000		-4,317,000	-8,511,000	-22,611,000
proceeds from borrowings, net of discounts and expenses																																																					0	104,000	986,876,000
obligations under securities lending																																																					31,173,000	22,263,000	-83,516,000
repayment of long-term debt
adjustments to reconcile net income to net cash flows from operating activities
depreciation and amortization of fixed & intangible assets
accrued expenses and other liabilities
repurchase of senior notes																																																																-1,000	0
proceeds from line of credit
in process research & development																																																							25,000,000
minority interest of subsidiaries																																																							2,710,000
realized (gain) loss on sale of marketable securities and strategic investment																																																							-5,267,000		-10,668,000
purchase of common stock																																																							-240,219,000
non-cash interest income																																																								1,360,000
acquired in process research & development and license
gain on settlement of license agreement																																																													0
facility impairment and (gain) loss on sale
proceeds from sale of amevive																																																												0	0
acquired in process research & development
stock-based compensation																																																										29,859,000	29,560,000		36,434,000	42,005,000	23,620,000		2,836,000	8,778,000	7,851,000
facility impairment and (gain) loss on disposition
proceeds from the sale of a strategic investment
net cash flows from (used in) investing activities
proceeds from issuance of stock for share based payment arrangements
proceeds of loan from joint venture partner
repayments of loan to joint venture partner																																																										0	-3,703,000
non-cash financing transaction:
see note 14 “indebtedness” and note 16 “tender offer” for a discussion of non-cash financing transactions that occurred during the six months ended june 30, 2007.
non-cash interest expense and amortization of investment premium																																																											437,000	898,000			-108,000	-7,547,000	1,718,000	8,257,000	16,753,000
realized loss on sale of marketable securities																																																											245,000		662,000	954,000	804,000
gain on sale of long-lived assets
acquisition of syntonix, net of cash acquired																																																											-42,289,000
proceeds from issuance of stock for share-based payment arrangements																																																											22,908,000
adjustments to reconcile net income to net cash flows from
operating activities
acquisition of in process research and development																																																												0
(gain) loss on settlement of license agreements
stock based compensation
realized (gain) loss on investments and other
impairment of property, plant and equipment																																																																807,000	-3,156,000	0	6,223,000
impairment of investments																																																															2,107,000
changes in, net of assets and liabilities acquired:
other long-term liabilities																																																												3,525,000	2,426,000	2,149,000	3,605,000	3,191,000	1,356,000	-5,339,000	7,639,000
acquisition of fumapharm, net of cash acquired
acquisition of conforma, net of cash acquired
issuance of stock for stock based compensation arrangements
proceeds from joint venture partner
repayments to joint venture partner
facility impairments and (gain) loss on sale
tax benefit from stock options																																																													-2,052,000	4,954,000	-15,195,000	13,490,000	-5,694,000	1,131,000	16,438,000
deferred revenue																																																													-15,456,000	189,000	2,298,000	-1,675,000	2,214,000	-4,389,000	7,083,000
payments for acquisition of fumapharm, net of cash acquired																																																													0
payments for acquisition of conforma, net of cash acquired																																																													0
acquisitions of property, plant and equipment																																																													-54,118,000	-14,092,000	-65,630,000	-102,426,000	-59,734,000	-90,370,000	-65,846,000
issuance of treasury stock for stock-based compensation arrangements																																																													12,351,000	18,131,000	56,356,000
loan proceeds from joint venture partner																																																													73,000	10,790,000	4,441,000
cash paid during the period for tax liabilities																																																													118,372,000
cash paid during the period for interest
acquisition of in process research & development
non-cash interest income and amortization of investment premium
impact of inventory step-up related to inventory sold																																																														919,000	4,002,000
facility impairments and loss on sale																																																														-800,000	-298,000	15,208,000
effect of exchange rate changes on cash & cash equivalents
cash flows from operating activities
other current and other assets																																																															-3,880,000	21,059,000	-4,427,000	835,000	14,758,000
cash flows from investing activities
purchases of marketable securities available-for-sale																																																															-596,216,000	-211,572,000	-626,988,000	-205,272,000	-290,452,000
proceeds from sales and maturities of marketable securities available-for-sale																																																															357,877,000	245,659,000	260,093,000	921,543,000	354,839,000
cash flows from financing activities
write-off of acquired in-process research and development
realized gain on sale of marketable securities available-for-sale																																																																			1,679,000
cash received from acquisition of biogen, inc., net of cash paid
restricted cash
proceeds from sale of manufacturing facility																																																																0	0
issuance of common stock for option exercises and employee stock purchase plan
issuance of treasury stock for option exercises and employee stock purchase plan																																																																		14,523,000	49,910,000
change in cash overdraft.
proceeds from loan
supplemental cash flow data
realized loss on sale of marketable securities available-for-sale																																																																	1,678,000
impact of inventory step-up																																																																	4,235,000	4,541,000	3,537,000
purchases of investments and other assets																																																																	-107,665,000	-6,338,000	-3,255,000
issuance of common stock for stock-based compensation arrangements
loss on sale of manufacturing facility
increase in investments and other assets
proceeds from issuance of notes payable

We provide you with 20 years of cash flow statements for Biogen stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Biogen stock. Explore the full financial landscape of Biogen stock with our expertly curated income statements.

The information provided in this report about Biogen stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.